Deadly drug-resistant infections are surging in European hospitals
Bloodstream infections caused by treatment-resistant Klebsiella pneumoniae surged 72% in European hospitals between 2019 and 2025, putting the European Union far off its 2030 target of a 5% reduction, according to new European Centre for Disease Prevention and Control (ECDC) reports. Several strains now resist nearly all antibiotics, including the newest treatments, and carry a 40% to 70% mortality rate. Overall, antimicrobial resistance kills roughly 35,000 people annually across the EU, Iceland, and Norway.
Christian Giske, who leads this work at the ECDC, described Klebsiella pneumoniae as the agency's "biggest concern" of the past year. While hospital hygiene measures helped cut MRSA bloodstream infections by 19% over the same period—beating a 15% goal—Klebsiella is a gut bacterium with stronger bodily reservoirs that can spread if even tiny surfaces go undisinfected. Drug-resistant E. coli cases also rose 16.4%, missing a 10% reduction target.
EU antibiotic consumption fell only 5% from 2019 to 2025, trailing the 20% target for 2030, though WHO-recommended drug usage reached 62.5% toward a 65% goal. ECDC Director Pamela Rendi-Wagner noted genomic surveillance is speeding up outbreak tracking, while EU pharmaceutical legislation due in December uses market monopoly perks and steady payment models to spur new antibiotics.
Continue in the app — vote & join in ➔